BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission on April 30, 2020.
April 30, 2020
· 1 min read